Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials-Reference-Cited by-同舟云学术

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

Published:2017-11-03 Issue:4 Volume:32 Page:971-978
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Arana P, ,Paiva B,Cedena M-T,Puig N,Cordon L,Vidriales M-B,Gutierrez N C,Chiodi F,Burgos L,Anglada L-L,Martinez-Lopez J,Hernandez M-T,Teruel A-I,Gironella M,Echeveste M-A,Rosiñol L,Martinez R,Oriol A,De la Rubia J,Orfao A,Blade J,Lahuerta J-J,Mateos M-V,San Miguel J-F

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017320.pdf

Reference42 articles.

1. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195–1206.

2. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med [Internet] 2008; 359: 906–917.

3. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142–152.

4. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055–1066.

5. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621–631.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma;Clinical and Experimental Medicine;2024-01-27

2. Plasma Cell Dyscrasias;Tata Memorial Centre Textbook of Oncology;2024

3. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM);Annals of Hematology;2023-12-05

4. CD38 expression by plasma cells In extramedullary multiple myeloma;Haematologica;2023-11-09

5. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice;Clinical Lymphoma Myeloma and Leukemia;2023-11